Table 2.
Clinical characteristics and treatment outcomes of Pseudomonas aeruginosa and P. putida keratitis
| Characteristics |
P. aeruginosa
(n = 33) |
P. putida
(n = 16) |
p-value (x2-test) |
|---|---|---|---|
| Central lesion‡ | 24 (72.7) | 12 (75.0) | 1.000* |
| Epithelial defect size ≥5 mm2 | 21 (63.6) | 9 (56.3) | 0.619 |
| Hypopyon | 15 (45.5) | 1 (6.3) | 0.006 |
| Epithelial healing time ≥ 10 days | 20 (60.6) | 9 (56.3) | 0.771 |
| Complications** | 5 (15.2) | 3 (18.8) | 1.000* |
| Surgical treatment++ | 5 (15.2) | 2 (12.5) | 1.000* |
| Presenting BCVA§ | |||
| mean ± SD, logMAR | 1.66 ± 0.95 | 1.53 ± 1.10 | 0.675† |
| < 0.1, Snellen | 20 (62.5) | 9 (56.3) | 0.676 |
| Final BCVA§ | |||
| mean ± SD, logMAR | 0.98 ± 1.12 | 1.09 ± 1.22 | 0.760† |
| < 0.1, Snellen | 9 (28.1) | 6 (37.5) | 0.509 |
| Decreased BCVA#§ | 8 (25.0) | 5 (31.3) | 0.735* |
| Clinical outcome§¶ | |||
| Good | 11 (34.4) | 7 (43.8) | 0.527 |
| Moderate | 11 (34.4) | 3 (18.8) | 0.328* |
| Poor | 10 (31.2) | 6 (37.5) | 0.665 |
BCVA best corrected visual acuity, logMAR logarithm of the minimum angle of resolution, SD standard deviation
Values indicate numbers (proportion) unless otherwise noted
*The p-value was calculated using Fisher’s exact test
†The p-value was calculated using independent t-test
‡Corneal lesion is located within the 1/2 radius from the center of the cornea
**Complicated cases in P. aeruginosa group were persistent epithelial defect (two cases), impending corneal perforation (two cases), and progression of infection (one case); those in P. putida group was persistent epithelial defect (three cases)
++Surgical treatment cases in P. aeruginosa group were amniotic membrane transplantation (three cases), tarsorrhaphy (one case), and evisceration (one case); those in P. putida group was amniotic membrane transplantation (two cases)
§Total n = 48: One young child in the P. aeruginosa group who could not read letters was excluded
#Cases of final BCVA worsened from presentation
¶The clinical outcomes were assessed at the end of three months or at the completion of treatment and classified into three groups, as defined by Green [11].